verified SJR 6,974 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Oxford University Press

workspace_premium Q1 — Oncology lock_open Open Access Unclaimed

Neuro-Oncology

Neuro-Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 178. It has an SJR impact factor of 6,974 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 6,974.

Neuro-Oncology focuses its scope in these topics and keywords: glioblastoma, glioma, tumor, brain, cell, cells, central, diagnosis, disease, leukocyte, ...

ISSN: 1522-8517

Editorial: Oxford University Press

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

6,974 Q1

H-index 178

Tasa de Aceptación pie_chart

22% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

NPD Open Access

Ruta Non-OA 3465 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

6,974

H-index

178

Docs (year)

250

Docs 3y

766

Total refs

11044

Cites 3y

8721

Citable 3y

519

Cites/Doc 2y

8.79

Ref/Doc

44.18

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

3465 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer

Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients

Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models

DRES-07. SIGNIFICANT SEX DIFFERENCES IN TEMOZOLOMIDE EFFICACY IN GLIOBLASTOMA (GBM) ARE DETECTABLE IN CELL AND PATIENT BASED EVALUATIONS

Diagnostic and prognostic significance of genetic regional heterogeneity

Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein

Consensus Conference on Cancer Registration of Brain and Central Nervous

Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning

CNS Cancer Models

Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years

Cereport(R) (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone

Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma

SHOW MORE ARTICLES

CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2

A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma

Brain tumors in children with neurofibromatosis: Additional neuropsychological morbidity?

Biology and management of ependymomas

Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34

Atypical white matter volume development in children following

ATPS-74IS MORE CHEMOTHERAPY BETTER? PROLONGED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA RECEIVING MORE THAN SIX CYCLES OF ADJUVANT TEMOZOLOMIDE

An independently validated survival nomogram for lower-grade glioma

AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor

A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.